Revance Therapeutics RVNC Stock
Revance Therapeutics Price Chart
Revance Therapeutics RVNC Financial and Trading Overview
Revance Therapeutics stock price | 3.65 USD |
Previous Close | 28.45 USD |
Open | 28.24 USD |
Bid | 0 USD x 800 |
Ask | 0 USD x 1200 |
Day's Range | 27.91 - 28.97 USD |
52 Week Range | 12.34 - 37.98 USD |
Volume | 1.46M USD |
Avg. Volume | 1.27M USD |
Market Cap | 2.41B USD |
Beta (5Y Monthly) | 0.843661 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 USD |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 40.45 USD |
RVNC Valuation Measures
Enterprise Value | 2.55B USD |
Trailing P/E | N/A |
Forward P/E | -21.578947 |
PEG Ratio (5 yr expected) | -0.78 |
Price/Sales (ttm) | 15.398599 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 16.297 |
Enterprise Value/EBITDA | -11.216 |
Trading Information
Revance Therapeutics Stock Price History
Beta (5Y Monthly) | 0.843661 |
52-Week Change | 122.30% |
S&P500 52-Week Change | 20.43% |
52 Week High | 37.98 USD |
52 Week Low | 12.34 USD |
50-Day Moving Average | 31.95 USD |
200-Day Moving Average | 28.03 USD |
RVNC Share Statistics
Avg. Volume (3 month) | 1.27M USD |
Avg. Daily Volume (10-Days) | 1.34M USD |
Shares Outstanding | 84.04M |
Float | 75.76M |
Short Ratio | 10.63 |
% Held by Insiders | 2.55% |
% Held by Institutions | 95.97% |
Shares Short | 15.13M |
Short % of Float | 20.66% |
Short % of Shares Outstanding | 18.01% |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -224.64% |
Operating Margin (ttm) | -171.086% |
Gross Margin | -0.77% |
EBITDA Margin | -145.30% |
Management Effectiveness
Return on Assets (ttm) | -28.21% |
Return on Equity (ttm) | N/A |
Income Statement
Revenue (ttm) | 156.64M USD |
Revenue Per Share (ttm) | 2.06 USD |
Quarterly Revenue Growth (yoy) | 95.29% |
Gross Profit (ttm) | -20388000 USD |
EBITDA | -227592000 USD |
Net Income Avi to Common (ttm) | -351872992 USD |
Diluted EPS (ttm) | -4.53 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 273.95M USD |
Total Cash Per Share (mrq) | 3.26 USD |
Total Debt (mrq) | 435.72M USD |
Total Debt/Equity (mrq) | N/A |
Current Ratio (mrq) | 4.142 |
Book Value Per Share (mrq) | -0.317 |
Cash Flow Statement
Operating Cash Flow (ttm) | -201778000 USD |
Levered Free Cash Flow (ttm) | -107327504 USD |
Profile of Revance Therapeutics
Country | United States |
State | TN |
City | Nashville |
Address | 1222 Demonbreun Street |
ZIP | 37203 |
Phone | 615 724 7755 |
Website | https://www.revance.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 534 |
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids; and OPUL Relational Commerce Platform, a financial technology platform. It has a collaboration and license agreement with Viatris Inc. to develop, manufacture, and commercialize onabotulinumtoxinA. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Q&A For Revance Therapeutics Stock
What is a current RVNC stock price?
Revance Therapeutics RVNC stock price today per share is 3.65 USD.
How to purchase Revance Therapeutics stock?
You can buy RVNC shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Revance Therapeutics?
The stock symbol or ticker of Revance Therapeutics is RVNC.
Which industry does the Revance Therapeutics company belong to?
The Revance Therapeutics industry is Biotechnology.
How many shares does Revance Therapeutics have in circulation?
The max supply of Revance Therapeutics shares is 104.39M.
What is Revance Therapeutics Price to Earnings Ratio (PE Ratio)?
Revance Therapeutics PE Ratio is 0.00000000 now.
What was Revance Therapeutics earnings per share over the trailing 12 months (TTM)?
Revance Therapeutics EPS is 0 USD over the trailing 12 months.
Which sector does the Revance Therapeutics company belong to?
The Revance Therapeutics sector is Healthcare.
Revance Therapeutics RVNC included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
NASDAQ Composite IXIC | 15603.26 USD — |
+0.1
|
10.08B USD — | 14784.03 USD — | 16292.28 USD — | — - | 10.08B USD — |
NASDAQ Biotechnology Total Retu XNBI | 4172.84 USD — |
-1.22
|
— — | 4004.28 USD — | 4291.75 USD — | — - | — — |
Nasdaq US 700 Small Cap Index NQUS700SC | 1913.4 USD — |
-1.32
|
— — | 1835.13 USD — | 2001.25 USD — | — - | — — |
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2497.76 USD — |
-0.11
|
— — | 2369.22 USD — | 2594.76 USD — | — - | — — |
NASDAQ Biotechnology NBI | 3856.67 USD — |
-1.22
|
— — | 3700.88 USD — | 3966.57 USD — | — - | — — |
NASDAQ HealthCare IXHC | 865.57 USD — |
-0.49
|
— — | 828.4 USD — | 890 USD — | — - | — — |
NASDAQ Composite Total Return I XCMP | 19098.57 USD — |
+0.1
|
— — | 18095.83 USD — | 19941.93 USD — | — - | — — |
NASDAQ Global Market Composite NQGM | 1638.71 USD — |
-0.55
|
— — | 1547.55 USD — | 1705.12 USD — | — - | — — |
Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}